ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2323

Evaluation of Case-Finding Algorithms for Identification of Patients with Dermatomyositis

Kevin Byram1 and Narender Annapureddy2, 1Internal Medicine, Vanderbilt University, Nashville, TN, 2Rheumatology and Immunology, Vanderbilt University, Nashville, TN

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: administrative databases, dermatomyositis, myopathy and myositis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Muscle Biology, Myositis and Myopathies - Poster II: Clinical

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: In order to enable meaningful clinical care and research, accurate algorithms are needed to identify patients with dermatomyositis (DM). In this study, we aimed to evaluate DM case-finding algorithms in a large health administrative database.

Methods: 100 patients were randomly selected from the Vanderbilt Synthetic Derivative, a de-identified version of the medical record, using the International Classification of Diseases version 9 (ICD9) code for DM: 710.3.  We developed 13 algorithms using combinations of frequency of ICD9 code, clinic encounter (defined as two ICD9 codes at least three months apart in one year), provider specialty (Rheumatology, Neurology, or Dermatology), use of immunosuppressant medications (prednisone alone or other immunosuppressants), Current Procedural Terminology code (for electromyogram or skin or muscle biopsy), and creatine kinase level over 600 IU/L. Diagnosis was confirmed by manual review of the de-identified chart using documented diagnosis of DM or DM sine myositis by rheumatologist, dermatologist, or neurologist as the gold standard. Age, ANA status, chart length, and number and type of Bohan and Peter (B&P) criteria were extracted from each chart. Patients with DM sine myositis or incomplete medical records were excluded from analysis of test characteristics with B&P criteria.

Results: Of the 100 patients reviewed, sixty-four were diagnosed as having DM by provider documentation and forty met threshold for diagnosis of as least “possible” DM by B&P criteria. Table 1 shows the algorithm characteristics, including positive predictive value (PPV), cohort sensitivity, and specificity in both subsets of patients.  Table 2 shows characteristics of DM patients found with the algorithms. An algorithm of clinic encounter and prednisone dose of at least 20mg daily had the highest PPV and specificity in each group (PPV: 95.3, 96.8; specificity: 94.4, 97). Provider specialty and immunosuppressant medications separately had high sensitivity in each group (sensitivity > 95%).

Conclusion: An algorithm of clinic encounter with prednisone dosage of at least 20mg daily had the highest PPV. An algorithm of 3 or more instances of ICD9 code 710.3had well performing test characteristics as well, with cohort sensitivity and positive predictive value. These algorithms can be used to identify cohorts of patients with rare disease in electronic medical records or administrative database and enable further study of outcomes and quality improvement. Macintosh HD:Users:kevinbyram:Desktop:Screen Shot 2016-06-21 at 8.00.09 AM.png

Macintosh HD:Users:kevinbyram:Desktop:Screen Shot 2016-06-21 at 8.00.35 AM.png


Disclosure: K. Byram, None; N. Annapureddy, None.

To cite this abstract in AMA style:

Byram K, Annapureddy N. Evaluation of Case-Finding Algorithms for Identification of Patients with Dermatomyositis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-case-finding-algorithms-for-identification-of-patients-with-dermatomyositis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-case-finding-algorithms-for-identification-of-patients-with-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology